4.7 Article

Long runs of homozygosity are associated with Alzheimer's disease

期刊

TRANSLATIONAL PSYCHIATRY
卷 11, 期 1, 页码 -

出版社

SPRINGERNATURE
DOI: 10.1038/s41398-020-01145-1

关键词

-

资金

  1. Fundacion bancaria La Caixa
  2. Fundacio ACE
  3. ISCIII (Ministry of Health, Spain)
  4. Grifols SA
  5. Piramal AG
  6. Laboratorios Echevarne
  7. Araclon Biotech S.A.
  8. European Union/EFPIA Innovative Medicines Initiative Joint Undertaking ADAPTED project [115975]
  9. European Union/EFPIA Innovative Medicines Initiative Joint Undertaking MOPEAD project [115985]
  10. ISCIII (Instituto de Salud Carlos III)-Subdireccion General de Evaluacion
  11. Fondo Europeo de Desarrollo Regional (FEDER-Una manera de Hacer Europa)
  12. Consejeria de Salud de la Junta de Andalucia [PI-0001/2017]
  13. National Institutes of Health [R01AG044546, P01AG003991, RF1AG053303, R01AG058501, U01AG058922, RF1AG058501, R01AG057777]
  14. Alzheimer's Association [NIRG-11-200110, BAND-14-338165, AARG-16-441560, BFG-15-362540, ADGC-10-196728]
  15. NIH [P50 AG05681, P01 AG03991, P01 AG026276]
  16. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  17. DOD ADNI (Department of Defense) [W81XWH12-2-0012]
  18. National Institute on Aging
  19. National Institute of Biomedical Imaging and Bioengineering
  20. AbbVie
  21. Alzheimer's Drug Discovery Foundation
  22. Araclon Biotech
  23. BioClinica, Inc.
  24. Biogen
  25. Bristol-Myers Squibb Company
  26. CereSpir, Inc.
  27. Cogstate
  28. Eisai Inc.
  29. Elan Pharmaceuticals, Inc.
  30. Eli Lilly and Company
  31. EuroImmun
  32. F. Hoffmann-La Roche Ltd and its Genentech, Inc.
  33. Fujirebio
  34. GE Healthcare
  35. IXICO Ltd.
  36. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  37. Johnson & Johnson Pharmaceutical Research & Development LLC.
  38. Lumosity
  39. Lundbeck
  40. Merck Co., Inc.
  41. Meso Scale Diagnostics, LLC.
  42. NeuroRx Research
  43. Neurotrack Technologies
  44. Novartis Pharmaceuticals Corporation
  45. Pfizer Inc.
  46. Piramal Imaging
  47. Servier
  48. Takeda Pharmaceutical Company
  49. Transition Therapeutics
  50. Canadian Institute of Health Research
  51. EFPIA companies
  52. SMEs as part of InnoMed (Innovative Medicines in Europe)
  53. European Union under the Sixth Framework program priority FP6-2004LIFESCIHEALTH-5
  54. NIA Division of Neuroscience [U01-AG032984]
  55. NIA [P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, P30AG10161, R01AG15819, R01AG17917, R01AG30146, R01AG36836, U01AG32984, U01AG46152, AG081220]
  56. NINDS [R01 NS080820]
  57. CurePSP Foundation
  58. Mayo Foundation
  59. Fundacion Alzheimur (Murcia)
  60. Ministerio de Educacion y Ciencia (Gobierno de Espana)
  61. Corporacion Tecnologica de Andalucia
  62. Agencia IDEA (Consejeria de Innovacion, Junta de Andalucia)
  63. Diabetes Research Laboratory
  64. Biomedical Research Foundation
  65. CIBER de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM)
  66. Illinois Department of Public Health
  67. Translational Genomics Research Institute
  68. Kronos Life Sciences Laboratories
  69. National Institute on Aging (Arizona Alzheimer's Disease Center) [P30 AG19610, RO1 AG023193]
  70. National Institute on Aging (Mayo Clinic Alzheimer's Disease Center) [P50 AG16574]
  71. National Institute on Aging (Intramural Research Program)
  72. National Alzheimer's Coordinating Center [U01 AG016976]
  73. state of Arizona
  74. French National Foundation on Alzheimer's Disease and Related Disorders
  75. LABEX (laboratory of excellence program investment for the future) DISTALZ grant
  76. Inserm
  77. Institut Pasteur de Lille
  78. Universite de Lille 2
  79. Lille University Hospital
  80. Medical Research Council [503480]
  81. Alzheimer's Research UK [503176]
  82. Wellcome Trust [082604/2/07/Z]
  83. German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) [01GI0102, 01GI0711, 01GI0420]
  84. NIH/NIA [U01 AG016976, R01 AG033193, U01 AG032984, U24 AG021886]
  85. AGES contract [N01-AG-12100]
  86. NHLBI [R01 HL105756]
  87. Icelandic Heart Association
  88. Erasmus Medical Center
  89. Erasmus University
  90. [PI13/02434]
  91. [PI16/01861]
  92. [PI17/01474]
  93. [PI19/01301]

向作者/读者索取更多资源

Research suggests that Alzheimer's disease cases have increased homozygosity compared to controls, indicating that recessive effects may contribute to a portion of AD heritability.
Long runs of homozygosity (ROH) are contiguous stretches of homozygous genotypes, which are a footprint of inbreeding and recessive inheritance. The presence of recessive loci is suggested for Alzheimer's disease (AD); however, their search has been poorly assessed to date. To investigate homozygosity in AD, here we performed a fine-scale ROH analysis using 10 independent cohorts of European ancestry (11,919 AD cases and 9181 controls.) We detected an increase of homozygosity in AD cases compared to controls [beta(AVROH) (CI 95%) = 0.070 (0.037-0.104); P = 3.91 x 10(-5); beta(FROH) (CI95%) = 0.043 (0.009-0.076); P = 0.013]. ROHs increasing the risk of AD (OR > 1) were significantly overrepresented compared to ROHs increasing protection (p < 2.20 x 10(-16)). A significant ROH association with AD risk was detected upstream the HS3ST1 locus (chr4:11,189,482-11,305,456), (beta (CI 95%) = 1.09 (0.48 - 1.48), p value = 9.03 x 10(-4)), previously related to AD. Next, to search for recessive candidate variants in ROHs, we constructed a homozygosity map of inbred AD cases extracted from an outbred population and explored ROH regions in whole-exome sequencing data (N = 1449). We detected a candidate marker, rs117458494, mapped in the SPON1 locus, which has been previously associated with amyloid metabolism. Here, we provide a research framework to look for recessive variants in AD using outbred populations. Our results showed that AD cases have enriched homozygosity, suggesting that recessive effects may explain a proportion of AD heritability.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据